In 10-15% of cancers, homozygous deletion of MTAP results in accumulation of MTA, which competes with SAM for the PRMT5 cofactor binding pocket, inhibiting methyltransferase activity (Fig. 1B)17. The gene discussed is PRMT5; the disease is cancer.